Halozyme Therapeutics, Inc. $HALO Shares Sold by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 36.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,925 shares of the biopharmaceutical company’s stock after selling 13,869 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $1,245,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth about $33,000. Brooklyn Investment Group raised its holdings in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 670 shares during the period. CWM LLC lifted its stake in Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 438 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Halozyme Therapeutics in the first quarter worth about $89,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO opened at $72.66 on Friday. The stock has a fifty day moving average price of $69.38 and a 200 day moving average price of $63.72. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1 year low of $46.26 and a 1 year high of $79.50. The stock has a market cap of $8.54 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same period in the prior year, the firm posted $1.27 EPS. The business’s revenue was up 22.1% compared to the same quarter last year. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the topic of several analyst reports. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Weiss Ratings restated a “buy (b)” rating on shares of Halozyme Therapeutics in a report on Wednesday, November 19th. Finally, Benchmark lifted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $75.10.

Insider Activity at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at approximately $1,840,207.26. This trade represents a 45.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 110,227 shares of company stock valued at $8,028,955. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.